Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study

NCT02936037 is registered in ClinicalTrials.gov with MedDay Pharmaceuticals SA as lead sponsor.

NCT NCT02936037
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02936037 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Lead sponsor
MedDay Pharmaceuticals SA
Phase
Phase 3
Overall status
Terminated
Start date
December 31, 2016
Completion date
April 23, 2020
Enrollment
642 (actual)
Sites
92

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis